APA

Fenske T. S., Shah N. M., Kim K. M., Saha S., Zhang C., Baim A. E., Farnen J. P., Onitilo A. A., Blank J. H., Ahuja H., Wassenaar T., Qamar R., Mansky P., Traynor A. M., Mattison R. J. & Kahl B. S. (20160201). A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. : Cancer.

Chicago

Fenske Timothy S, Shah Namrata M, Kim Kyung Mann, Saha Sandeep, Zhang Chong, Baim Arielle E, Farnen John P, Onitilo Adedayo A, Blank Jules H, Ahuja Harish, Wassenaar Tim, Qamar Rubina, Mansky Patrick, Traynor Anne M, Mattison Ryan J and Kahl Brad S. 20160201. A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. : Cancer.

Harvard

Fenske T. S., Shah N. M., Kim K. M., Saha S., Zhang C., Baim A. E., Farnen J. P., Onitilo A. A., Blank J. H., Ahuja H., Wassenaar T., Qamar R., Mansky P., Traynor A. M., Mattison R. J. and Kahl B. S. (20160201). A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. : Cancer.

MLA

Fenske Timothy S, Shah Namrata M, Kim Kyung Mann, Saha Sandeep, Zhang Chong, Baim Arielle E, Farnen John P, Onitilo Adedayo A, Blank Jules H, Ahuja Harish, Wassenaar Tim, Qamar Rubina, Mansky Patrick, Traynor Anne M, Mattison Ryan J and Kahl Brad S. A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study. : Cancer. 20160201.